|
|
|
|
LEADER |
01525nam a2200313 u 4500 |
001 |
EB001888658 |
003 |
EBX01000000000000001052019 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
200106 r ||| eng |
100 |
1 |
|
|a Ho, Chuong
|
245 |
0 |
0 |
|a Sequencing of pharmacological management of Crohn's disease and ulcerative colitis
|h Elektronische Ressource
|b a review of guidelines
|c Chuong Ho, Charlene Argáez
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c January 31, 2019, 2019
|
300 |
|
|
|a 1 PDF file (11 pages)
|b illustration
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Evidence-Based Practice
|
653 |
|
|
|a Guidelines as Topic
|
653 |
|
|
|a Crohn Disease / drug therapy
|
653 |
|
|
|a Colitis, Ulcerative / drug therapy
|
700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK541237
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a This Rapid Response report aims to review the evidence-based guidelines associated with the early (first line) use of biologics in the sequencing of pharmacological treatments for patients with moderate to severe Crohn's disease and ulcerative colitis
|